KONVI
27.6.2024 09:01:30 CEST | Business Wire | Press release
Konvi, Europe’s leading luxury assets fractional investment platform, has announced the launch of a once-in-a-lifetime opportunity to invest in an exclusive Birkin bag designed by Alec Monopoly. This is a particularly exciting investment as it combines a piece of art by a prestigious artist with one of the best investment vehicles in the world – the Birkin bag – and the firm expects a high degree of interest from investors.
The value of a Birkin bag increases immediately upon leaving the store, leading many to say it’s a better investment than gold. Having never fluctuated downwards in value, Birkins are highly lucrative investments that consistently outperform the S&P 500 and boast double-digit annual returns.
Alec Monopoly rose to fame through his bright-coloured graffiti art and paintings which explore the themes of capitalism and luxury lifestyles. Birkin bags designed by Monopoly retail between an astounding $11,900 and $300,000. The famous handbags have also been sported by celebrities, including Khloe Kardashian, who owns a $25,000 piece painted by the artist.
Luxury assets are much more than a popular accessory, as they provide strong investment opportunities. The fact that returns on luxury items are negatively correlated with those on equities, bonds, and other collectible investments, makes them a great addition to an investment portfolio to ensure strong diversification.
Through Konvi’s app, investors can buy fractional shares of the luxury Birkin bag starting from €250 with immediate effect. Konvi buys and insures the asset and then sells it at the highest price, returning money to the asset's co-owners. This model enables users to access an extremely rare investment that would usually require significant capital and a broad network of collectors and auction houses to invest in.
Eran Peer, Co-Founder and CEO, commented: “Launching this exclusive luxury Alec Monopoly Birkin bag investment opportunity for Konvi users is central to our goal of bringing previously inaccessible luxury investment opportunities to a broader range of people. This offering means people can own a share in a bag adorned by some of the biggest celebrities on the planet, including the Kardashians, and reap the investment rewards. We’re excited to be bringing such a high-performing asset to our platform and look forward to launching similar investment opportunities in the near future.”
Investing in luxury assets such as art, fine wines, whiskeys, watches and vintage cars has long been inaccessible to the majority of people. High up-front costs, low availability and opaque, private markets with high fees mean historically only the most sophisticated investors and wealthy individuals could capitalise on these opportunities.
Konvi is the first Pan-European investment platform that enables retail investors to diversify their portfolios by fractionally investing in luxury assets. By collaborating with industry experts with strong track records, Konvi ensures that investment opportunities on its platform are carefully curated and accessible to everyone. Konvi also recently launched its latest Banksy art investment with one of the leading Banksy art piece curators, TGB Contemporary.
Visit Konvi’s website to find out how you can invest in this Alec Monopoly Birkin bag: https://konvi.app/en_GB/
About Konvi
Konvi is a pioneering online platform that democratises access to alternative investments, including hand-curated art, fine wine, classic cars, and more. With a user-friendly interface and innovative strategies, Konvi empowers individuals to build diversified portfolios and achieve their financial goals starting from an investment of €250.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627487145/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom